These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 19745661)

  • 21. Nationwide use of medicines for Alzheimer's disease by community-dwelling persons in Finland.
    Alander J; Lönnroos E; Hartikainen S; Klaukka T
    J Am Geriatr Soc; 2006 Mar; 54(3):557-8. PubMed ID: 16551340
    [No Abstract]   [Full Text] [Related]  

  • 22. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating response to metrifonate.
    Tariot PN
    J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [How long should drug therapy be continued for Alzheimer disease?].
    Nakamura Y
    Seishin Shinkeigaku Zasshi; 2009; 111(1):43-8. PubMed ID: 19378499
    [No Abstract]   [Full Text] [Related]  

  • 26. [Are Alzheimer's drugs effective?].
    Hilkka S; Pirttilä T
    Duodecim; 2005; 121(4):345-6. PubMed ID: 15799249
    [No Abstract]   [Full Text] [Related]  

  • 27. Alpha-tocopherol and Alzheimer's disease.
    Kilander L; Ohrvall M
    N Engl J Med; 1997 Aug; 337(8):572-3. PubMed ID: 9265107
    [No Abstract]   [Full Text] [Related]  

  • 28. Should titration schedules for cholinesterase inhibitors be changed?
    Sikdar S
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1063-4. PubMed ID: 14618560
    [No Abstract]   [Full Text] [Related]  

  • 29. [Alzheimer dementia. Intervening as early as possible].
    MMW Fortschr Med; 2002 Jan; 144(1-2):67. PubMed ID: 11847891
    [No Abstract]   [Full Text] [Related]  

  • 30. [Could intake of vitamins C and E inhibit development of Alzheimer dementia?].
    Landmark K
    Tidsskr Nor Laegeforen; 2006 Jan; 126(2):159-61. PubMed ID: 16415937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Time-limited contribution concerning anti-dementia agents].
    Pedersen T; Hansen FR; Abelskov K
    Ugeskr Laeger; 2002 Oct; 164(43):5040; author reply 5040-1. PubMed ID: 12422402
    [No Abstract]   [Full Text] [Related]  

  • 32. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical treatment of Alzheimer's disease: past, present, and future.
    Ott BR
    Med Health R I; 2002 Jul; 85(7):210-2. PubMed ID: 12182092
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescribing Cholinesterase Inhibitors for Alzheimer Disease: Timing Matters.
    Regenold WT; Loreck DJ; Brandt N
    Am Fam Physician; 2018 Jun; 97(11):700. PubMed ID: 30215946
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of a cholinesterase inhibitor on the vitality in Alzheimer disease].
    Toba K; Moriya Y; Nakai R; Iwata A; Kobayashi Y; Sonohara K; Hasegawa H; Kozaki K
    Nihon Ronen Igakkai Zasshi; 2009 May; 46(3):269-70. PubMed ID: 19521049
    [No Abstract]   [Full Text] [Related]  

  • 37. Vitamin E for Alzheimer's disease?
    Simonson W
    Geriatr Nurs; 2014; 35(2):147-8. PubMed ID: 24703434
    [No Abstract]   [Full Text] [Related]  

  • 38. Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside.
    Walia V; Kaushik D; Mittal V; Kumar K; Verma R; Parashar J; Akter R; Rahman MH; Bhatia S; Al-Harrasi A; Karthika C; Bhattacharya T; Chopra H; Ashraf GM
    Mol Neurobiol; 2022 Jan; 59(1):657-680. PubMed ID: 34751889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MG; Tabet N
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.